February 12, 2021 – Pfizer Inc. and BioNTech SE announced that the U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 Vaccine.
This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.
Consistent with the agreements for the prior 200 million doses, the U.S. government will pay $1.95 billion for the additional 100 million doses. Eligible U.S. residents will continue to receive the vaccine for free, consistent with the U.S. government’s commitment for free access for COVID-19 vaccines.
Pfizer’s facility in Kalamazoo, Michigan, remains the primary manufacturing site of the Pfizer-BioNTech COVID-19 Vaccine in the U.S. The vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the U.S., United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.